CCN1 and prostate cancer: Numerous studies have shown CYR61 might serve as a marker for different cancer, such as breast cancer [48], lung cancer [49], prostate cancer [50], etc. Our study further demonstrated that high expression of CALD1 was associated with poor prognosis of platinum-resistant OC, and revealed CALD1 could be used as a potential target for platinum-resistant OC.